CClinicalTrials.gg
RecruitingNCT07679594Updated Jul 6, 2026

A Post-market Prospective Clinical Study of Eurosilicone Luna Mammary Implants

An observational study in Breast Augmentation, Breast Reconstruction and Breast Revision-Augmentation, sponsored by GCA (Eurosilicone). Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by GCA (Eurosilicone) · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The goal of this observational, non-comparative study is to determine the frequency and rate of rupture and capsular contracture Baker III-IV of Eurosilicone Luna range of breast implants, over a 10-year period following surgical implantation in female population between 18 and 65 years old undergoing primary or revision of breast augmentation or breast reconstruction.

02

Conditions studied

  • Breast Augmentation
  • Breast Reconstruction
  • Breast Revision-Augmentation
  • Breast Reconstruction With Silicone Implants
  • Breast Reconstruction, Revision Breast Reconstruction
  • Breast Augmentation and Breast Reconstruction

Keywords

  • Luna XT
  • Anatomical breast implant
  • Mammary implant
03

In context

Lead sponsor

GCA (Eurosilicone) is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients from centers participating to the study.

Eligibility criteria

Inclusion Criteria:

  • The target population includes subjects undergoing augmentation or reconstructive breast implant surgery in which the Eurosilicone Luna mammary implant is recommended.

Inclusion criteria are:

  1. Genetic female subjects aged between 18 and 65 years old.
  2. Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:

i. Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs (synthetic or natural).

ii. Primary breast augmentation (cosmetic surgery) with or without mastopexy iii. Breast revision surgery with or without mastopexy c) Subjects who have received a Eurosilicone Luna implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow-up appointments as per the study protocol.

Exclusion criteria are:

  1. Subjects with a BMI >35.
  2. Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
  3. Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer-related clinical studies.
  4. Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
  5. Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
  6. Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
  7. Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
  8. Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
  9. Subjects with a known history of compromised wound healing.
  10. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
  11. Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants.
  12. Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aesthetic indications

    Primary or revision breast augmentation with or without mastopexy.

    Procedure: Breast augmentation surgery

  • Medical indications

    Primary or revision of breast reconstruction. Immediate or delayed reconstruction. With or without associated chemotherapy and/or radiotherapy.

    Procedure: Breast reconstruction surgery

Interventions

  • ProcedureBreast augmentation surgery

    The procedure is carried out at the surgeon's discretion. This includes the incision location, the implant placement, the intraoperative applications.

    Also known as: Cosmetic breast implant surgery, Aesthetic breast implant surgery

  • ProcedureBreast reconstruction surgery

    The procedure is carried out at the surgeon's discretion. This includes the incision location, the implant placement, the intraoperative applications.

    Also known as: Immediate breast reconstruction, Delayed breast reconstruction

06

What researchers measure

Primary outcomes

  1. Frequency and rate of implant rupture

    Time frame: 10 years

  2. Frequency and rate of capsular contracture Baker III-IV

    Time frame: 10 years

Secondary outcomes

  1. Rate of the secondary surgical procedures required for correction of complications

    Time frame: 10 years

  2. Rate and frequency of local complications

    These complications may be related to the device itself or to the surgical procedure: * Capsular contracture of Baker Grade I-II * Haematoma * Rupture * Seroma * Severe and continuing pain * Post-operative infection * Explantation as a result of infection * Implant displacement/extrusion * Implant misplacement/malrotation * Wrinkling/folds * Breast Implant Associate Anaplastic Large Cell Lymphoma * Breast Implant Ilness (BII)/ Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (Asia) * Delayed or abnormal wound healing occurring within the first 3 months of surgery * Any other complications considered by the Investigator to be related to the device or surgical procedure

    Time frame: 10 years

  3. Patient satisfaction

    This will be determined using a questionnaire assessing the qualify of life.

    Time frame: 10 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679594
Lead sponsor
GCA (Eurosilicone)
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Mar 30, 2026
Primary completion
Dec 31, 2038 (estimated)
Completion
Dec 31, 2038 (estimated)
Last update
Jul 6, 2026

Study contacts

GCA Clinical affairs department
Contact
luna10PMCF@gcaesthetics.com
+33 783326098

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion